Tinzaparin
- Generic Name
- Tinzaparin
- Brand Names
- Innohep
- Drug Type
- Small Molecule
- CAS Number
- 9041-08-1
- Unique Ingredient Identifier
- 7UQ7X4Y489
- Background
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
- Indication
Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.
- Associated Conditions
- Clotting, Deep Vein Thrombosis, Pulmonary embolism, Deep vein thrombosis, Venous Thromboembolism
Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 616
- Registration Number
- NCT01455831
- Locations
- 🇧🇪
Ghent University Hospital, Ghent, Belgium
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?
- Conditions
- Fetal Growth Retardation
- Interventions
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 50
- Registration Number
- NCT01390051
- Locations
- 🇩🇰
Consultant phD professor Anne-Mette Hvas, Aarhus, Central Denmark Region, Denmark
🇩🇰Department of Obstetrics, Randers, Denmark
Venous Thromboembolism Prophylaxis Post Cesarean Section
- Conditions
- BleedingVenous Thromboembolism
- Interventions
- Drug: PLACEBO
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2012-02-06
- Lead Sponsor
- King Saud University
- Target Recruit Count
- 300
- Registration Number
- NCT01321788
- Locations
- 🇸🇦
Security Forces Hospital, Riyadh, Saudi Arabia
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 900
- Registration Number
- NCT01130025
- Locations
- 🇨🇦
Diamond Health Care Centre, Vancouver, British Columbia, Canada
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 131
- Registration Number
- NCT00981903
- Locations
- 🇺🇸
Cornell Weill Scholl of Medicine, New York, New York, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer
- Conditions
- Pulmonary EmbolismDeep Vein ThrombosisCancer
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 18
- Registration Number
- NCT00967148
- Locations
- 🇨🇦
Ottawa Health Research Institute, Ottawa, Ontario, Canada
Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 13
- Registration Number
- NCT00851864
- Locations
- 🇨🇦
Calgary Health Region, Calgary, Alberta, Canada
Tinzaparin in the Treatment of the Acute Pulmonary Embolism
- First Posted Date
- 2008-07-08
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Complejo Hospitalario Xeral-Calde
- Target Recruit Count
- 102
- Registration Number
- NCT00711308
- Locations
- 🇪🇸
Pneumology Service. Hospital do Meixoeiro, Vigo, Pontevedra, Spain
🇪🇸Pneumology Service. Hospital Clínico, Santiago de Compostela, A Coruña, Spain
🇪🇸Pneumology Service. Hospital Xeral Cies, Vigo, Pontevedra, Spain
Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- Hospital Universitari de Bellvitge
- Target Recruit Count
- 241
- Registration Number
- NCT00689520
- Locations
- 🇪🇸
Vascular surgery service. Hospital Creu Roja de l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Department of Vascular Surgery. Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Duke University
- Target Recruit Count
- 40
- Registration Number
- NCT00629447
- Locations
- 🇺🇸
Duke University Health Systems, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.